- Trials with a EudraCT protocol (50)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
50 result(s) found for: Antiviral protein.
Displaying page 1 of 3.
EudraCT Number: 2010-022568-11 | Sponsor Protocol Number: AI452-008 | Start Date*: 2011-04-20 | |||||||||||
Sponsor Name:Bristol Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS-790052 or BMS-6500... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024307-27 | Sponsor Protocol Number: LUMC2010-03 | Start Date*: 2011-11-01 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | ||
Medical condition: CMV reactivation after allogeneic stem cell transplantation | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004036-30 | Sponsor Protocol Number: ALS-8176-502 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Alios BioPharma | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respirator... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-005081-60 | Sponsor Protocol Number: RENAL-AAD | Start Date*: 2017-04-21 |
Sponsor Name:Jose Luis Calleja Panero | ||
Full Title: MULTICENTER CLINICAL TRIAL TO DETERMINE THE INFLUENCE OF TREATMENT WITH DIRECT ANTIVIRAL AGENTS IN THE GLOMERULAR AND TUBULAR FUNCTION OF PATIENTS WITH CHRONIC HCV HEPATITIS | ||
Medical condition: Hepatitis C | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018295-24 | Sponsor Protocol Number: AI444-010 | Start Date*: 2010-07-12 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and 4 Infection Revised Protocol Number ... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) FR (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010149-29 | Sponsor Protocol Number: AI444-014 | Start Date*: 2009-05-07 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus Genotype 1 Infection | |||||||||||||
Medical condition: Chronic Hepatitis C Virus Genotype 1 Infection in Treatment Naïve Subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001201-48 | Sponsor Protocol Number: MONTBLANC | Start Date*: 2023-02-16 | |||||||||||
Sponsor Name:Klinikum der Ludwig-Maximillians-Universität München | |||||||||||||
Full Title: Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) | |||||||||||||
Medical condition: non-resectable hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000438-38 | Sponsor Protocol Number: CRO 682 | Start Date*: 2007-04-12 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Efficacy of Lopinavir in Pregnancy: Pharmacokinetic and Virological Studies with Kaletra melt extruded tablet formulation | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004201-25 | Sponsor Protocol Number: 1B | Start Date*: 2011-11-30 |
Sponsor Name:Erasmus MC | ||
Full Title: The BOKITO-1B Study: Tenofovir DF Bone and Kidney Toxicity. Pharmacology in HBV monoinfected patients. | ||
Medical condition: Chronic hepatitis B | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000785-37 | Sponsor Protocol Number: GS-US-320-1092 | Start Date*: 2016-08-26 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Adolescents with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic Hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA BE (Completed) IT (Prematurely Ended) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001390-76 | Sponsor Protocol Number: ESCAPE | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: A phase 3, randomized, open-labeled, multi-center study comparing clinical efficacy and safety of intravenous sarilumab plus standard of care compared to standard of care, in the treatment of patie... | |||||||||||||
Medical condition: Covid-19 coronavirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022110-29 | Sponsor Protocol Number: SG006 | Start Date*: 2010-10-08 |
Sponsor Name:Synairgen Research Limited | ||
Full Title: A randomised, double-blind, placebo-controlled Phase II study, comparing the efficacy and safety of inhaled SNG001 to placebo administered to COPD patients after the onset of a respiratory viral in... | ||
Medical condition: Prevention or attenuation of COPD symptoms caused by respiratory viruses | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019378-34 | Sponsor Protocol Number: AI444-011 | Start Date*: 2010-09-06 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Prior Treatment with... | |||||||||||||
Medical condition: Chronic Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013657-14 | Sponsor Protocol Number: AI438006 | Start Date*: 2009-11-10 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Randomized, Open label, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068 in HIV-1 Infected Subjects | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006239-11 | Sponsor Protocol Number: HBV 09-01 | Start Date*: 2009-05-15 | |||||||||||
Sponsor Name:Stichting Lever Onderzoek | |||||||||||||
Full Title: Augmenting response to entecavir using a temporary peginterferon alpha-2a add-on strategy for the treatment of HBeAg-positive chronic hepatitis B (ARES study) | |||||||||||||
Medical condition: Chronic hepatitis B virus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006009-18 | Sponsor Protocol Number: TMC278-TiDP15-C221 | Start Date*: 2009-04-17 | |||||||||||
Sponsor Name:Tibotec Pharmaceuticals | |||||||||||||
Full Title: An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy. | |||||||||||||
Medical condition: HIV-1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002843-81 | Sponsor Protocol Number: 057 | Start Date*: 2020-01-07 |
Sponsor Name:IMEA | ||
Full Title: Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication | ||
Medical condition: HIV-1-infected patient Age > 65 years old Plasma HIV RNA ≤ 50 copies/mL for ≥ 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening. Currently receiving an ant... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003768-31 | Sponsor Protocol Number: NNF18OC0052256 | Start Date*: 2019-12-05 |
Sponsor Name:Lungemedicinsk Forskningsenhed | ||
Full Title: Effects of azithromycin treatment on anti-viral immunity in patients with asthma and COPD. | ||
Medical condition: COPD and asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000180-13 | Sponsor Protocol Number: CLDT600A2409 | Start Date*: 2011-02-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: OPTIMA: A Randomized, Open-label, 104-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Road... | |||||||||||||
Medical condition: Treatment in HBeAg-negative chronic hepatitis B patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) GR (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000274-20 | Sponsor Protocol Number: GNT-WAS-03 | Start Date*: 2014-05-14 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08) | |||||||||||||
Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopeni... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
